<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04174313</url>
  </required_header>
  <id_info>
    <org_study_id>Nestor Pistillo</org_study_id>
    <nct_id>NCT04174313</nct_id>
  </id_info>
  <brief_title>Ventilator-induced Lung Injury Vortex in Patients With SARS-CoV-2</brief_title>
  <acronym>VILIVORTEX</acronym>
  <official_title>Ventilator-induced Lung Injury Vortex in Patients With SARS-CoV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital El Cruce</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital El Cruce</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The concept of Ventilator-induced Lung Injury Vortex (VILI vortex) has recently been proposed&#xD;
      as a progressive lung injury mechanism in which the alveolar stress/strain increases as the&#xD;
      ventilable lung &quot;shrinks&quot; (1). This positive feedback inexorably leads to the acceleration of&#xD;
      lung damage, with potentially irreversible results. Little is known about the clinical&#xD;
      aspects of this condition. Understanding its behavior could contribute to changing its&#xD;
      potential devastating impact.&#xD;
&#xD;
      The objective of this study is to evaluate the incidence of VILI vortex in patients with&#xD;
      acute respiratory syndrome (ARDS) secondary to COVID-19, to establish a connection between&#xD;
      this phenomenon and mortality, and to identify the factors that have an impact on its&#xD;
      development.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mechanical ventilation is an essential tool for the treatment of patients with acute&#xD;
      respiratory distress syndrome (ARDS). However, as with other strategies, it is not free of&#xD;
      complications. Inadequate ventilation may have a negative impact on pulmonary and systemic&#xD;
      hemodynamics, and it could both cause structural damage to pulmonary parenchyma and activate&#xD;
      inflammation (2). This process is known as ventilator-induced lung injury (VILI) and may&#xD;
      promote the development of multiple organ failure and, eventually, death.&#xD;
&#xD;
      VILI results from the interaction between the mechanical load applied to the ventilable lung&#xD;
      and its capacity to tolerate it. Factors such as tidal volume (Vt), driving pressure (ΔP),&#xD;
      inspiratory flow rate (VI), respiratory rate (RR), excessive inspiratory effort, high levels&#xD;
      of FiO2 and, in some cases, PEEP, have been involved in damage mechanism. In that sense, the&#xD;
      concept of mechanical power (MP) tries to encompass most of these factors within a measurable&#xD;
      unit (3). Furthermore, the decrease in ventilable lung volume (baby lung concept), the&#xD;
      heterogeneous lung compromise in ARDS), and the presence of cofactors that have a negative&#xD;
      impact on the lung (fluid overload, presence of sepsis or shock) could increase its&#xD;
      susceptibility to damage (4-5).&#xD;
&#xD;
      Due to the fact that the mechanical conditions of the lung change dynamically with the&#xD;
      progression of the disease, the ventilatory strategy needs constant adjustments in order to&#xD;
      maintain a balance between the load and the size of the ventilable lung (concept of ergonomic&#xD;
      ventilation). In fact, a protective ventilatory strategy of low tidal volume (Vt: 6&#xD;
      ml/kg/PBW) and limited plateau pressure (PPlat &lt;30 cmH2O) may cause damage if the functional&#xD;
      residual capacity (FRC) decreases significantly, thus making a lower number of alveoli&#xD;
      (including capillaries) withstand a higher mechanical load per unit.&#xD;
&#xD;
      The concept of VILI vortex has recently been proposed as a progressive lung injury mechanism&#xD;
      in which the alveolar stress/strain increases as the ventilable lung &quot;shrinks&quot;. This positive&#xD;
      feedback inexorably leads to the acceleration of lung damage, with potentially irreversible&#xD;
      results (1). Little is known about the clinical aspects of this condition. Understanding its&#xD;
      behavior could contribute to changing its potential devastating impact.&#xD;
&#xD;
      The objective of this study is to evaluate the incidence of VILI vortex in patients with ARDS&#xD;
      secondary to COVID-19, to establish a connection between this phenomenon and mortality, and&#xD;
      to identify the factors that have an impact on its development.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Actual">June 9, 2021</completion_date>
  <primary_completion_date type="Actual">March 11, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Survived and Died</measure>
    <time_frame>90 days</time_frame>
    <description>The number of patients who died and survived was compared between patients with SARS-CoV-2 who progressed with VILI VORTEX and without VILI VORTEX)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With and Without Refractory Hypoxemia</measure>
    <time_frame>90 days</time_frame>
    <description>The number of patients that evolved with refractory hypoxemia was compared between the patients with SARS-CoV-2 that evolved with VILI VORTEX and without VILI VORTEX) Refractory hypoxemia was defined as PaO2/FiO2 &lt;100 despite the optimization of mechanical ventilation and prone positioning.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Complications</measure>
    <time_frame>90 days</time_frame>
    <description>The following variables and complications were also observed during the period of analysis: incidence of pneumonia associated with mechanical ventilation, need for noradrenaline over 0.1 γ/kg/min for more than 24 h, positive blood cultures, accumulated fluid balance, dialysis treatment, clinical and/or echocardiographic evidence of heart failure, lactate ≥2 mmol/L in at least two consecutive samples, presence of persistent fever (≥38º at least once a day for three consecutive days), and the highest value of ferritin, D-dimer, C-reactive protein, troponin I and LDH obtained during the first 14 days of invasive mechanical ventilation.&#xD;
VILI vortex patients had positive blood cultures, moderate to severe shock, persistent fever and fluid balance was considerably more positive.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">65</enrollment>
  <condition>ARDS</condition>
  <condition>Mechanical Ventilation Complication</condition>
  <condition>Ventilator-Induced Lung Injury</condition>
  <arm_group>
    <arm_group_label>VILI VORTEX and No VILI VORTEX</arm_group_label>
    <description>Measurement of pulmonary pressures and volumes in the same patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CT scan</intervention_name>
    <description>Mechanical variables and PaO2/FiO2 were registered daily for 14 days or until initiating assisted ventilation. These data were obtained in passive mechanical conditions.&#xD;
Ventilator-induced lung injury vortex was defined as a progressive increase in driving pressure (ΔP) as Vt remained constant or even decreased.&#xD;
Refractory hypoxemia was defined as PaO2/FiO2 &lt;100 despite the optimization of mechanical ventilation and prone positioning.</description>
    <arm_group_label>VILI VORTEX and No VILI VORTEX</arm_group_label>
    <other_name>Transpulmonary pressures (TP) will be measured</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with SARS-CoV-2 in mechanical ventilation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: ARDS&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with do-not-resuscitate (DNR) orders and pregnant women. Cardiac arrest before ICU&#xD;
        admission. Extra corporeal membrane oxygenation (ECMO) requirement within the first 24 h of&#xD;
        ICU admission and chronic obstructive pulmonary disease with gold class 3 or 4, or home&#xD;
        oxygen therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nestor Pistillo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital El Cruce</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nestor Pistillo</name>
      <address>
        <city>Avellaneda</city>
        <state>Buenos Aires</state>
        <zip>1870</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <reference>
    <citation>Marini JJ, Gattinoni L. Time Course of Evolving Ventilator-Induced Lung Injury: The &quot;Shrinking Baby Lung&quot;. Crit Care Med. 2020 Aug;48(8):1203-1209. doi: 10.1097/CCM.0000000000004416.</citation>
    <PMID>32697492</PMID>
  </reference>
  <reference>
    <citation>Beitler JR, Malhotra A, Thompson BT. Ventilator-induced Lung Injury. Clin Chest Med. 2016 Dec;37(4):633-646. doi: 10.1016/j.ccm.2016.07.004. Epub 2016 Oct 14. Review.</citation>
    <PMID>27842744</PMID>
  </reference>
  <reference>
    <citation>Gattinoni L, Pesenti A. The concept of &quot;baby lung&quot;. Intensive Care Med. 2005 Jun;31(6):776-84. Epub 2005 Apr 6.</citation>
    <PMID>15812622</PMID>
  </reference>
  <reference>
    <citation>Gattinoni L, Tonetti T, Quintel M. Regional physiology of ARDS. Crit Care. 2017 Dec 28;21(Suppl 3):312. doi: 10.1186/s13054-017-1905-9. Review.</citation>
    <PMID>29297365</PMID>
  </reference>
  <reference>
    <citation>Vasques F, Duscio E, Cipulli F, Romitti F, Quintel M, Gattinoni L. Determinants and Prevention of Ventilator-Induced Lung Injury. Crit Care Clin. 2018 Jul;34(3):343-356. doi: 10.1016/j.ccc.2018.03.004. Review.</citation>
    <PMID>29907269</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <results_first_submitted>July 23, 2021</results_first_submitted>
  <results_first_submitted_qc>August 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 30, 2021</results_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital El Cruce</investigator_affiliation>
    <investigator_full_name>Nestor Pistillo</investigator_full_name>
    <investigator_title>Head of Intensive Care Unit at Hospital El Cruce</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Ventilator-Induced Lung Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 25, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT04174313/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited between March 2020 to March 2021</recruitment_details>
      <pre_assignment_details>No patients with SARS-CoV-2 were excluded from the study prior to group assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>VILI VORTEX</title>
          <description>Clinical categorization of patients with SARS-CoV-2 with VILI vortex</description>
        </group>
        <group group_id="P2">
          <title>NO VILI VORTEX</title>
          <description>Clinical categorization of patients with SARS-CoV-2 without VILI vortex</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VILI VORTEX</title>
          <description>Participants who evolved with VILI vortex clinical criteria</description>
        </group>
        <group group_id="B2">
          <title>No VILI VORTEX</title>
          <description>Participants who evolved without clinical criteria for VILI vortex</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="55" upper_limit="60"/>
                    <measurement group_id="B2" value="60" lower_limit="54" upper_limit="66"/>
                    <measurement group_id="B3" value="60" lower_limit="55" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Percentage of male and female patients</title>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbidities</title>
          <description>Risk factors at the time of admission</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes Mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obesity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ischemic heart disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cancer/immunosupresion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Survived and Died</title>
        <description>The number of patients who died and survived was compared between patients with SARS-CoV-2 who progressed with VILI VORTEX and without VILI VORTEX)</description>
        <time_frame>90 days</time_frame>
        <population>The evolution of the patients was compared with Chi square, significant p &lt;0.05</population>
        <group_list>
          <group group_id="O1">
            <title>VILI VORTEX</title>
            <description>Patients who evolved with clinical criteria of VILI VORTEX</description>
          </group>
          <group group_id="O2">
            <title>No VILI VORTEX</title>
            <description>Patients who evolved without clinical criteria of VILI VORTEX</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Survived and Died</title>
          <description>The number of patients who died and survived was compared between patients with SARS-CoV-2 who progressed with VILI VORTEX and without VILI VORTEX)</description>
          <population>The evolution of the patients was compared with Chi square, significant p &lt;0.05</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Survivors</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Dead</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With and Without Refractory Hypoxemia</title>
        <description>The number of patients that evolved with refractory hypoxemia was compared between the patients with SARS-CoV-2 that evolved with VILI VORTEX and without VILI VORTEX) Refractory hypoxemia was defined as PaO2/FiO2 &lt;100 despite the optimization of mechanical ventilation and prone positioning.</description>
        <time_frame>90 days</time_frame>
        <population>The baseline characteristics of the population were similar for both groups.</population>
        <group_list>
          <group group_id="O1">
            <title>No VILI VORTEX</title>
            <description>Participants who evolved without clinical criteria for VILI vortex</description>
          </group>
          <group group_id="O2">
            <title>VILI VORTEX</title>
            <description>Participants who evolved with VILI vortex clinical criteria</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With and Without Refractory Hypoxemia</title>
          <description>The number of patients that evolved with refractory hypoxemia was compared between the patients with SARS-CoV-2 that evolved with VILI VORTEX and without VILI VORTEX) Refractory hypoxemia was defined as PaO2/FiO2 &lt;100 despite the optimization of mechanical ventilation and prone positioning.</description>
          <population>The baseline characteristics of the population were similar for both groups.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>with refractory hypoxemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no refractory hypoxemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Complications</title>
        <description>The following variables and complications were also observed during the period of analysis: incidence of pneumonia associated with mechanical ventilation, need for noradrenaline over 0.1 γ/kg/min for more than 24 h, positive blood cultures, accumulated fluid balance, dialysis treatment, clinical and/or echocardiographic evidence of heart failure, lactate ≥2 mmol/L in at least two consecutive samples, presence of persistent fever (≥38º at least once a day for three consecutive days), and the highest value of ferritin, D-dimer, C-reactive protein, troponin I and LDH obtained during the first 14 days of invasive mechanical ventilation.&#xD;
VILI vortex patients had positive blood cultures, moderate to severe shock, persistent fever and fluid balance was considerably more positive.</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VILI VORTEX</title>
            <description>Participants who evolved with VILI vortex clinical criteria</description>
          </group>
          <group group_id="O2">
            <title>No VILI VORTEX</title>
            <description>Participants who evolved without clinical criteria for VILI vortex</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Complications</title>
          <description>The following variables and complications were also observed during the period of analysis: incidence of pneumonia associated with mechanical ventilation, need for noradrenaline over 0.1 γ/kg/min for more than 24 h, positive blood cultures, accumulated fluid balance, dialysis treatment, clinical and/or echocardiographic evidence of heart failure, lactate ≥2 mmol/L in at least two consecutive samples, presence of persistent fever (≥38º at least once a day for three consecutive days), and the highest value of ferritin, D-dimer, C-reactive protein, troponin I and LDH obtained during the first 14 days of invasive mechanical ventilation.&#xD;
VILI vortex patients had positive blood cultures, moderate to severe shock, persistent fever and fluid balance was considerably more positive.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>intranosocomial pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal replacement therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bood cultures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 12 weeks after entering the study</time_frame>
      <desc>Refractory hypoxemia was defined as PaO2/FiO2 &lt;100 despite the optimization of mechanical ventilation and prone positioning.</desc>
      <group_list>
        <group group_id="E1">
          <title>VILI VORTEX</title>
          <description>SARS-CoV-2 patients who evolved with VILI VORTEX</description>
        </group>
        <group group_id="E2">
          <title>NO VILI VORTEX</title>
          <description>SARS-CoV-2 patients who evolved without VILI VORTEX</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Intranosocomial pneumonia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Blood cultures</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Kidney Failure</sub_title>
                <description>AKI III: Increase in serum creatinine &gt;300% from baseline or serum creatinine ≥4.0 mg/dl(≥354 umol/L) after an increase of at least 44 umol/L or treatment with renal replacement therapy.</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Refractory hipoxemy</sub_title>
                <description>Refractory hypoxemia was defined as PaO2/FiO2 &lt;100 despite the optimization of mechanical ventilation and prone positioning.</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Persistent fever</sub_title>
                <description>Tº &gt;37.9</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lactate level &gt;2mmol/L</sub_title>
                <description>Lactate level&gt; 2 mmol / L is associated with shock</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nestor Pistillo</name_or_title>
      <organization>Hospital El Cruce</organization>
      <phone>054 1142109000 ext 5636</phone>
      <email>npistillo@yahoo.com.ar</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

